Computational Repurposing of FDA Approved Drugs Against Cyclin Dependent Kinase (CDK2)

Carteolol is identified as the primary FDA-approved candidate with the most balanced overall computational profile for potential binding to human CDK2, based on docking and interaction analyses.

• Why it matters: Finding new CDK2-targeting therapies is important, and drug repurposing can speed discovery by leveraging existing FDA-approved compounds.
• What they did: Using the Human CDK2 crystal structure (PDB ID: 3PY0), the study performed molecular docking, PLIP interaction profiling, then assessed drug-likeness and pharmacokinetics via Swiss ADME and predicted toxicity via ProTox Was.
• The result: Carteolol’s combined docking affinity, interaction profile, drug-likeness, pharmacokinetics, and toxicity predictions supported its selection, but experimental work is needed to confirm direct binding and inhibitory activity against CDK2.

AI summary of the abstract · may contain errors · not medical advice · read the paper.